Professor Johanna Olweus and her research team of 16 have received NOK 4.5 million in grants from the Danish Novo Nordisk Foundation. The money will be used to commercialize a whole new type of cancer immunotherapy that Olweus and her team are developing.
They have found a way to program cancer patients' immune cells to fight cancer using healthy human immune cells. This method allows the immune system to attack the cancer cells specifically, without harming other cells.
Published in major journals, first or last author from Oslo University Hospital.
Age Inherently Links to Histology to Define Histoprognostic Classification of Peripheral Neuroblastic Tumors
J Clin Oncol, JCO2001839 (in press)
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance
Eur Heart J (in press)
Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence
J Hepatol (in press)